Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMRZ1F2)

Drug Name

Padsevonil Drug Info

Synonyms

1294000-61-5; UNII-0R1HN52K0N; UCB0942; UCB1415943-000; (R)-4-(2-chloro-2,2-difluoroethyl)-1-((2-(methoxymethyl)-6-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl)methyl)pyrrolidin-2-one; (4R)-4-(2-Chloro-2,2-difluoroethyl)-1-((2-(methoxymethyl)-6-(trifluoromethyl)imidazo(2,1-b)(1,3,4)thiadiazol-5-yl)methyl)pyrrolidin-2-one; (4R)-4-(2-chloro-2,2-difluoroethyl)-1-[[2-(methoxymethyl)-6-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]methyl]pyrrolidin-2-one; Padsevonil [INN]; Padsevonil [USAN]; Padsevonil (JAN/USAN); SCHEMBL1672843; CHEMBL4297521; UCB-0942; WHO 10384; DB14977; SB18725; HY-109009; CS-0030507; D11842; Q27237119; (4R)-4-(2-Chloro-2,2-difluoroethyl)-1-((2-(methoxymethyl)-6-(trifluoromethyl)imidazo(2,1-b)(1,3,4)thiadiazol-5-yl)methyl)-2-pyrrolidinone; 2-Pyrrolidinone, 4-(2-chloro-2,2-difluoroethyl)-1-((2-(methoxymethyl)-6-(trifluoromethyl)imidazo(2,1-b)-1,3,4-thiadiazol-5-yl)methyl)-, (4R)-

Indication

Disease Entry	ICD 11	Status	REF
Epilepsy	8A60-8A68	Phase 2/3	[1]

Cross-matching ID

PubChem CID: 52911611
CAS Number: CAS 1294000-61-5
TTD Drug ID: DMRZ1F2

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Discontinued Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Synaptic vesicle glycoprotein 2A (SV2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Brivaracetam	DMSEPK8	Complex partial seizure	8A68.0	Approved	[3]
Levetiracetam	DMTGDN8	Epilepsy	8A60-8A68	Approved	[4]
Seletracetam	DM3IJMN	Epilepsy	8A60-8A68	Discontinued in Phase 3	[5]
------------------------------------------------------------------------------------

Drug(s) Targeting GABA(A) receptor (GABAR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PH94B NS	DMDC7OH	Social anxiety disorder	6B04	Phase 3	[6]
OV101	DMA6LR3	Angelman syndrome	LD90.0	Phase 3	[7]
BTD-001	DMS6ZA0	Narcolepsy	7A20	Phase 2	[8]
SAGE-324	DM5NC39	Essential tremor or related tremors	8A04.1	Phase 2	[9]
Evt201	DM8QXEY	Sleep-wake disorder	7A00-7B2Z	Phase 2	[10]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
GABA(A) receptor (GABAR)	TTCI43M	NOUNIPROTAC	Inhibitor	[2]
Synaptic vesicle glycoprotein 2A (SV2A)	TTT3P91	SV2A_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT03370120) Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy. U.S. National Institutes of Health.
2	Pharmacological Profile of the Novel Antiepileptic Drug Candidate Padsevonil: Characterization in Rodent Seizure and Epilepsy Models. J Pharmacol Exp Ther. 2020 Jan;372(1):11-20.
3	Pharmacological management of epilepsy: recent advances and future prospects. Drugs. 2008;68(14):1925-39.
4	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5	Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22.
6	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7	Gaboxadol in Fragile X Syndrome: A 12-Week Randomized, Double-Blind, Parallel-Group, Phase 2a Study. Front Pharmacol. 2021 Oct 8;12:757825.
8	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
10	The partial positive allosteric GABA(A) receptor modulator EVT 201 is efficacious and safe in the treatment of adult primary insomnia patients. Sleep Med. 2009 Sep;10(8):859-64.